Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Curis, Inc. is a biotechnology company focused on developing targeted cancer therapies, primarily through small molecule inhibitors like emavusertib targeting IRAK4. It operates in immuno-oncology and precision oncology, collaborating with partners such as Aurigene and Genentech. The company advances drug candidates through preclinical and clinical trials, seeking regulatory approvals and licensing its technologies to generate revenue from royalties and milestone payments.
This description was generated via AI from an annual report. Updated about 1 year ago.